Zacks: Analysts Anticipate Seres Therapeutics Inc (MCRB) Will Post Earnings of -$0.42 Per Share

Brokerages expect that Seres Therapeutics Inc (NASDAQ:MCRB) will announce earnings per share (EPS) of ($0.42) for the current quarter, according to Zacks. Three analysts have made estimates for Seres Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.49) and the highest estimate coming in at ($0.40). Seres Therapeutics posted earnings of ($0.68) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 38.2%. The firm is scheduled to issue its next earnings report on Thursday, August 1st.

According to Zacks, analysts expect that Seres Therapeutics will report full year earnings of ($1.90) per share for the current financial year, with EPS estimates ranging from ($2.31) to ($1.26). For the next year, analysts expect that the company will report earnings of ($1.96) per share, with EPS estimates ranging from ($2.52) to ($1.21). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.12). The firm had revenue of $7.32 million during the quarter, compared to analyst estimates of $8.61 million. Seres Therapeutics had a negative return on equity of 1,583.95% and a negative net margin of 301.60%.

A number of equities analysts have commented on MCRB shares. Cowen restated a “buy” rating on shares of Seres Therapeutics in a research note on Friday, February 8th. BidaskClub downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 3rd. Oppenheimer restated a “buy” rating on shares of Seres Therapeutics in a research note on Tuesday, March 19th. Jefferies Financial Group started coverage on Seres Therapeutics in a research note on Tuesday, April 30th. They issued a “hold” rating and a $7.00 target price for the company. Finally, ValuEngine downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 5th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $11.13.

NASDAQ:MCRB opened at $4.60 on Monday. The stock has a market capitalization of $196.43 million, a P/E ratio of -1.89 and a beta of 1.80. Seres Therapeutics has a one year low of $4.42 and a one year high of $9.75.

A number of hedge funds have recently modified their holdings of MCRB. BlackRock Inc. boosted its stake in Seres Therapeutics by 1.8% in the third quarter. BlackRock Inc. now owns 2,281,563 shares of the biotechnology company’s stock valued at $17,318,000 after acquiring an additional 40,719 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Seres Therapeutics by 6.4% during the third quarter. JPMorgan Chase & Co. now owns 421,494 shares of the biotechnology company’s stock valued at $3,199,000 after buying an additional 25,287 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Seres Therapeutics by 3.4% during the third quarter. Renaissance Technologies LLC now owns 756,608 shares of the biotechnology company’s stock valued at $5,743,000 after buying an additional 24,708 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Seres Therapeutics by 48.8% during the fourth quarter. Rhumbline Advisers now owns 27,136 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 8,895 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Seres Therapeutics by 7.6% during the fourth quarter. Bank of New York Mellon Corp now owns 85,364 shares of the biotechnology company’s stock valued at $386,000 after buying an additional 6,023 shares during the last quarter. Institutional investors own 79.26% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Featured Story: How do taxes affect a CDs total return?

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.